← Back to Search

Cell Therapy

Phase I for Respiratory Diseases (CYNKCOVID Trial)

Phase 1 & 2
Waitlist Available
Led By Corey Casper, MD MPH
Research Sponsored by Celularity Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights

CYNKCOVID Trial Summary

This trial is to test a new immunotherapy for safety and efficacy on patients with moderate COVID-19. The immunotherapy contains NK cells from the placenta.

Eligible Conditions
  • Respiratory Diseases
  • Lung Disease
  • Respiratory Infection
  • Viral Pneumonia
  • Immune Diseases
  • Acute Respiratory Distress Syndrome
  • Immune Factors
  • Drug Effects
  • Antiviral Agents
  • Antibiotics
  • Painkillers
  • Anticancer Drugs
  • RNA Virus Infections
  • Pneumonia
  • Viral Diseases
  • Coronavirus Infection
  • Coronavirus
  • COVID-19

CYNKCOVID Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Phase 1 Futility Check for go/no decision to move to Phase 2: Rate of clinical improvement
Phase 1: Frequency and Severity of Adverse Events (AE)
Phase 2: Time to Clinical Improvement by Ordinal Scale for Clinical Improvement (OSCI)
Secondary outcome measures
All-cause mortality rate
Duration of hospitalization
Impact of CYNK-001 on sequential organ failure assessment (SOFA) score
+13 more

CYNKCOVID Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Phase IExperimental Treatment1 Intervention
CYNK-001 infusions on Days 1, 4, and 7
Group II: Phase IIActive Control1 Intervention
Randomized, open label; CYNK-001 infusions on Days 1, 4, and 7 compared to Control Group: Best Supportive Care

Find a Location

Who is running the clinical trial?

Lung Biotechnology PBCIndustry Sponsor
13 Previous Clinical Trials
625 Total Patients Enrolled
Access to Advanced Health Institute (AAHI)OTHER
28 Previous Clinical Trials
1,580 Total Patients Enrolled
California Institute for Regenerative Medicine (CIRM)OTHER
64 Previous Clinical Trials
3,071 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Annals of Internal MedicineJournal
Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate
Levey, Andrew S., Josef Coresh, Tom Greene, Lesley A. Stevens, Yaping (Lucy) Zhang, Stephen Hendriksen, John W. Kusek, and Frederick Van Lente. 2006. “Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate”. Annals of Internal Medicine. American College of Physicians. doi:10.7326/0003-4819-145-4-200608150-00004.
clinicaltrials.govStudy
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
2020. "Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04365101.
All > Covid
~17 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top